Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3807611 | 1.00 | BRD4 (0.58) | BRD4LMNASMN1; SMN2POLBRAB9A | |
| SCHEMBL3807614 | 1.00 | BRD4 (0.58) | BRD4LMNASMN1; SMN2POLBRAB9A | |
| SCHEMBL3810595 | 0.86 | GAA (0.50) | BRD4POLBRAB9ANPC1GAA | |
| SCHEMBL4807142 | 0.85 | KDM4E (0.45) | BRD4LMNASMN1; SMN2POLBKDM4E | |
| SCHEMBL6211946 | 0.83 | CCR1 (0.47) | BRD4LMNAPOLBRAB9ANPC1 | |
| SCHEMBL4193569 | 0.82 | CYP19A1 (0.44) | BRD4POLBRAB9ANPC1MAPT | |
| SCHEMBL4185400 | 0.82 | CYP19A1 (0.44) | BRD4POLBRAB9ANPC1MAPT | |
| SCHEMBL4216922 | 0.80 | ALDH1A1 (0.51) | LMNASMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL4216929 | 0.80 | ALDH1A1 (0.51) | LMNASMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL11546122 | 0.79 | LMNA (0.75) | BRD4LMNASMN1; SMN2POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041905-A1 | Process for the Preparation of Substituted 2-Acetylamino-Alkoxyphenyl | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | US | disclosed |
| US-20080064884-A1 | Novel Process 1 | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| WO-2008010764-A2 | A PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-ACETYLAMINO-ALKOXYPHENYL | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | WO | disclosed |
| US-6951874-B2 | Compounds | ASTRAZENECA AB (SE) | 2005-10-04 | — | — | US | disclosed |
| US-6943188-B2 | Hydroxyalkyl compounds | ASTRAZENECA AB (SE) | 2005-09-13 | — | — | US | disclosed |
| US-6927222-B2 | 1,3,4,5-tetrahydro-pyrido(4,3-b)indole-2-yl derivative useful for treating rheumatoid arthritis, chronic obstructive pulmonary disease, asthma and multple sclerosis | ASTRAZENECA AB (SE) | 2005-08-09 | — | — | US | disclosed |
| EP-1263724-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | EP | disclosed |
| US-20030158225-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | US | disclosed |
| US-20030149047-A1 | Novel compounds | ASTRAZENCA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| US-20030144267-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
| EP-1263724-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001062728-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158225-A1 | Novel compounds | UGT2B7, RPS4Y1, RPS4X | BRD4 1249/4885LMNA 3735/4885SMN1; SMN2 2455/4885 |
| US-20080064884-A1 | Novel Process 1 | TPX2, UGT1A1, BRIX1 | BRD4 2423/4885LMNA 2842/4885SMN1; SMN2 1027/4885 |
| US-20030149047-A1 | Novel compounds | RPS4Y1, RPS4X, RPS6 | BRD4 1284/4885LMNA 3811/4885SMN1; SMN2 2698/4885 |
| US-20030144267-A1 | Novel compounds | RPS4X, RPS4Y1, UGT2B7 | BRD4 1259/4885LMNA 3715/4885SMN1; SMN2 2657/4885 |
| US-20100041905-A1 | Process for the Preparation of Substituted 2-Acetylamino-Alkoxyphenyl | F12, RPS4Y1, CCNA1 | BRD4 2714/4885LMNA 436/4885SMN1; SMN2 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.